[144] Stoke Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. (STOK) Form 144 notifies the SEC of a proposed sale of 10,000 common shares through Morgan Stanley Smith Barney LLC on 10/03/2025 with an aggregate market value of $248,200.00. The filer reports the shares were acquired the same day on 10/03/2025 by exercise of stock options and paid for in cash. The filing also discloses multiple prior sales by the same person or plan during the past three months, including 15,000+ shares sold across dates in August and September 2025 generating gross proceeds such as $300,491.78 and $205,680.00. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information and references reliance on Rule 10b5-1 sales where applicable.

Positive

• Transaction disclosed publicly via Form 144, supporting market transparency
• Shares acquired by exercise and sold through a registered broker (Morgan Stanley)

Negative

• Insider has sold multiple tranches in the past three months (Aug–Sep 2025), which may indicate ongoing dilution of insider holdings

Insights

Insider Transactions Counsel

Insider sold newly exercised shares via broker; plan-era 10b5-1 sales evident.

The filing shows a proposed sale of 10,000 shares acquired by option exercise on 10/03/2025, sold through Morgan Stanley. That same filer executed multiple recent 10b5-1 sales in Aug–Sep 2025, with disclosed gross proceeds (for example, $300,491.78).

This pattern is consistent with routine insider liquidity following option exercises and prearranged trading plans. The signature statement affirms no undisclosed material adverse information and, if a 10b5-1 plan is used, represents compliance as of the plan adoption date.

Equity Markets Analyst

Transaction size is modest relative to total shares outstanding; routine insider disposition.

The proposed sale of 10,000 shares equals an aggregate market value of $248,200 against 54,797,418 shares outstanding as stated, representing a ~0.018% portion of outstanding shares (calculated from disclosed figures).

Recent aggregated sales in the filing show several disbursements across Aug–Sep 2025, indicating ongoing, non-single-event liquidity rather than a single large exit.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	10000	248200.00	54797418	10/03/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/03/2025	Exercise of Stock Options	Issuer			10000	10/03/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for JONATHAN ALLAN 45 Wiggins Ave Bedford MA 01730	Common	09/03/2025	6345	127316.87
10b5-1 Sales for JONATHAN ALLAN 45 Wiggins Ave Bedford MA 01730	Common	09/02/2025	14922	300491.78
10b5-1 Sales for JONATHAN ALLAN 45 Wiggins Ave Bedford MA 01730	Common	08/29/2025	850	17000.00
JONATHAN D ALLAN 45 Wiggins Ave Bedford MA 01730	Common	08/18/2025	1683	30694.55
10b5-1 Sales for JONATHAN ALLAN 45 Wiggins Ave Bedford MA 01730	Common	08/13/2025	13712	205680.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did the Form 144 for STOK report?

The filing reports a proposed sale of 10,000 common shares on 10/03/2025 through Morgan Stanley with an aggregate market value of $248,200.00.

How were the 10,000 shares acquired?

The shares were acquired on 10/03/2025 by exercise of stock options, with payment in cash.

Does the filing show prior sales by the same person?

Yes; the filing lists multiple sales in Aug–Sep 2025, including transactions that generated proceeds of $300,491.78 and $205,680.00.

Was a Rule 10b5-1 plan referenced?

The filing includes entries labeled as 10b5-1 Sales for several transactions, indicating some sales were executed under prearranged plans.

What representation does the seller make in the Form 144?

The seller represents they do not know any material adverse information about the issuer that has not been publicly disclosed and, if relying on a 10b5-1 plan, makes that representation as of the plan adoption or instruction date.